Silver Coordination Complexes for Apoptosis-Inducing Antineoplastic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using cytotoxic heavy metals face challenges such as lack of specificity, difficulty in delivering agents to tumor sites, patient resistance, and adverse side effects, which hinder effective treatment of solid and disseminated tumors.
Innovation Solution
Development of a composition comprising a metal coordination complex of cytotoxic metals like silver, platinum, and chiral α-organic acids, specifically formed under low pH conditions with surfactants and amino acids, to induce apoptosis in tumor cells, enhancing silver coordination and cytotoxicity while minimizing toxicity to normal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytotoxic heavy metals are used for cancer treatment, then tumor cell destruction is achieved, but toxicity to normal tissues and adverse side effects increase
Solution Approach 1:
The patent applies local quality by designing coordination complexes where the cytotoxic metal center is surrounded by specific ligands (amino acids, chiral α-organic acids) that create a localized protective environment. This allows the complex to exert its cytotoxic effect selectively on tumor cells while the ligand shell reduces interaction with and toxicity to normal tissues, thereby resolving the contradiction between efficacy and normal tissue protection.
Solution Approach 2:
The invention uses composite materials by combining cytotoxic metal ions (silver, platinum) with biocompatible organic ligands (amino acids, chiral α-organic acids) to form coordination complexes. This composite structure integrates the high cytotoxicity of the metal center with the low toxicity and biocompatibility of the organic ligands, achieving both effective tumor cell destruction and reduced adverse side effects.
2Reliability
If metal coordination complexes are used to inhibit DNA replication, then cell division is blocked, but patient resistance and lack of specificity develop
Solution Approach 1:
The patent applies parameter changes by systematically varying the ligand composition (different amino acids, chiral α-organic acids), metal center (silver, platinum), and coordination geometry to create a library of complexes with different biological properties. This allows optimization of specificity for tumor cells and reduction of patient resistance through selection of complexes with appropriate parameters for the specific cancer type and patient condition.
3Reliability
If high concentrations of silver are administered, then cytotoxicity against tumors increases, but argyria and systemic distribution to tissues occur
Solution Approach 1:
The patent uses chiral α-organic acids and amino acids as intermediaries that mediate between the silver ion and the biological system. These intermediary ligands allow silver to maintain its cytotoxic activity against tumors while preventing direct interaction with proteins and tissues that would cause argyria and systemic toxicity, thus resolving the contradiction between effective dosage and safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The silver(I)-chiral α-organic acid coordination complex effectively inhibits tumor cell growth and induces apoptosis, demonstrating superior cytotoxicity to cisplatin in certain concentrations, with reduced side effects and improved delivery to both solid and disseminated tumors.
Implementation Method 1
Apoptosis-inducing antineoplastic silver (I) coordination complexes
Implementation Method 2
metal coordination complex of at least one cytotoxic metal and at least one chiral α-organic acid
Data Source
AI summary
The present invention describes chemotherapeutic compositions, a method for making the same, and methods for inducing apoptosis in tumor cells and/or inhibiting tumors. The compositions are metal coordination complexes of a cytotoxic metal, such as silver(I) and a chiral α-organic acid, such as tartaric acid, in a pharmaceutical carrier.